文献速递甲状腺疾病

一项探讨甲状腺癌放射性碘治疗后使用人工泪液对泪液放射性的影响的初步非随机对照试验

A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears After Radioactive Iodine Treatment for Thyroid Cancer.
PubMed 文献 · Thyroid · 2023-12-11

这项非随机前瞻性初步临床试验纳入8例接受放射性碘治疗的甲状腺癌患者,右眼自用不含防腐剂人工泪液、左眼为对照,第1天实验眼几何平均131I活度降低26%(p=0.008),4天几何平均曲线下面积降低23%(p=0.002)。结论认为频繁使用不含防腐剂人工泪液可能降低泪液中131I水平,未来需多中心临床试验确定其能否降低鼻泪管阻塞风险。

要点

  • 甲状腺癌放射性碘治疗后泪液中可检测到131I。
  • 第1天不含防腐剂人工泪液使实验眼几何平均131I活度降低26%(p=0.008)。
  • 4天几何平均曲线下面积降低23%(p=0.002),需多中心临床试验验证。

核心结论

  • 甲状腺癌放射性碘治疗后泪液中存在131I,从放射性碘摄入当天开始频繁使用不含防腐剂人工泪液可能降低泪液中131I水平。
  • 这一发现可能对降低鼻泪管阻塞风险有意义,未来需多中心临床试验确定放射性碘治疗后使用人工泪液是否可降低鼻泪管阻塞风险。

研究设计与样本

  • 非随机前瞻性初步临床试验,招募佩戴隐形眼镜并接受放射性碘治疗的甲状腺癌患者,右眼自用不含防腐剂人工泪液、左眼为对照。
  • 从放射性碘摄入当天开始右眼用不含防腐剂人工泪液共4天:第1天每15分钟1次共2小时,之后每30分钟1次至睡前;第2天每小时1次至少12小时;第3天每日4次;第4天每日2次。
  • 隐形眼镜每日更换,所有镜片一周后收集,用井型计数器测量131I活度、经衰变校正并换算为贝克勒尔。
  • 共纳入8例甲状腺癌患者的16只眼,接受131I平均145.7 mCi(范围108-159)。

主要发现

  • 第1天不含防腐剂人工泪液使实验眼几何平均131I活度降低26%(p=0.008)。
  • 不含防腐剂人工泪液使4天几何平均曲线下面积降低23%(p=0.002)。

局限性

  • 原文结论指出未来需多中心临床试验确定放射性碘治疗后使用人工泪液是否可降低鼻泪管阻塞风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Nasolacrimal duct obstruction (NLDO) is an adverse effect of high dose radioactive iodine (RAI) therapy for thyroid carcinoma. There are currently no established preventive measures. This study assesses whether preservative free artificial tears (PFATs) can decrease the 131I sodium iodide (131I) activity in the tears of patients following RAI therapy for thyroid carcinoma, and potentially serve as a preventive measure for RAI-associated NLDO. Methods: This non-randomized prospective pilot clinical trial recruited contact-lens wearing patients undergoing RAI therapy for thyroid cancer to self-administer PFATs into the right eye for four days starting on the day of RAI ingestion. Left eyes were the controls. While wearing contacts, patients self-administered PFATs per the following-Day 1: every 15 minutes for 2 hours, then every 30 minutes until bedtime, day 2: every hour for at least 12 hours, day 3: four times a day, and day 4: two times a day. Contact lenses were changed daily, and all lenses were collected one week later. Levels of 131I activity were measured by a well counter, decay-corrected, and converted to units of becquerel. Statistical analyses were performed to compare the 131I activities of the experimental and control eyes. Results: Sixteen eyes of eight patients treated with an average of 145.7 mCi (range 108-159) of 131I for papillary thyroid cancer were included. On day 1, artificial tears decreased the geometric mean 131I activity by 26% in the experimental eyes (p = 0.008). Artificial tears also decreased the geometric mean area under the curve over four days by 23% (p = 0.002). Conclusions: 131I is present in the tears following RAI therapy for thyroid carcinoma. Frequent PFATs starting on the day of RAI ingestion may decrease the level of 131I in the tears. This finding could have implications for lowering the risk of NLDO. Future multi-center clinical trials are needed to determine whether the use of artificial tears after RAI therapy may decrease the risk of NLDO. Clinical Trial Registration: NCT04327999.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lee IT, Grice JV, Ji X, et al. A Pilot Nonrandomized Controlled Trial Examining the Use of Artificial Tears on the Radioactivity of Tears After Radioactive Iodine Treatment for Thyroid Cancer. Thyroid. 2023. PMID: 37917111. doi:10.1089/thy.2023.0338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。